Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

Everyone knows Nvidia (NVDA) is a stock of a lifetime. It’s up 1,700%+ since we first recommended it in September 2018. And ...

Genetic medicines could treat certain diseases, however, the current delivery systems available—viral vectors and lipid nanoparticles (LNPs)—pose unique challenges for gene therapy applications. For ...

A large research team led by nanotechnologist Roy van der Meel rebuilt the body's own proteins and fats into nano-delivery ...

The mRNA technology that was deployed so effectively ... They also said they plan to discuss the phase 2b results with regulators. Vertex's gene-editing therapy for sickle cell disease, Casgevy ...

As the company invests heavily in expanding its non-COVID mRNA vaccine pipeline ... in accelerating drug development. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been ...